Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio
Source: SeekingAlpha
2026-03-10 10:41:06 ET
More on Esperion Therapeutics
- Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
- Esperion Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Esperion Therapeutics, Inc. (ESPR) Corstasis Therapeutics, - M&A Call - Slideshow
- Esperion Therapeutics GAAP EPS of $0.22 misses by $0.05, revenue of $168.45M beats by $2.33M
- Esperion Therapeutics Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio
Esperion Therapeutics Inc.
NASDAQ: ESPR
ESPR Trading
-5.87% G/L:
$2.755 Last:
5,824,220 Volume:
$3.12 Open:
ESPR Latest News
March 10, 2026 06:00:00 am
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ESPR Stock Data
$804,448,466
234,999,359
0.16%
70
N/A
Pharmaceuticals
Healthcare
US
Ann Arbor
